Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.48 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.41 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016206 | 0.76 | ADORA2A (0.47) | ADORA2AADORA1ALDH1A1KDM4EMAPT | |
| SCHEMBL5017656 | 0.71 | MYC (0.52) | ADORA2AADORA1ALDH1A1KDM4EMAPT | |
| SCHEMBL5024950 | 0.71 | MYC (0.55) | ADORA2AADORA1ALDH1A1KDM4EMAPT | |
| SCHEMBL5016332 | 0.71 | MYC (0.55) | ADORA2AADORA1ALDH1A1KDM4EMAPT | |
| SCHEMBL5017713 | 0.71 | ADORA2A (0.72) | ADORA2AADORA1MYCADORA3ADORA2B | |
| SCHEMBL5016171 | 0.69 | ADORA2A (0.60) | ADORA2AADORA1KDM4EMYCCYP19A1 | |
| SCHEMBL5022246 | 0.68 | ADORA2A (0.47) | CACNA1BAPBA1ADORA2AADORA1ALDH1A1 | |
| SCHEMBL5024974 | 0.67 | ADORA2A (0.56) | ADORA2AADORA1MYCADORA3ADORA2B | |
| SCHEMBL5016111 | 0.67 | ADORA2A (0.55) | ADORA2AADORA1ALDH1A1KDM4EMAPT | |
| SCHEMBL5025068 | 0.66 | MAPT (0.56) | CACNA1BAPBA1ADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | claimed |
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2005058883-A1 | 2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL PRODESFARMA AG (CH) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058356-A1 | 2,6 Bisheteroaryl-4-Aminopyrimidines as Adenosine Receptor Antagonists | ADORA2A, ADORA3, ADORA1 | CACNA1B 2714/4885APBA1 1178/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.